Order final: Divestiture on the clock
Hikma Pharmaceuticals may acquire Baxter Healthcare Corporation’s generic injectables business, a $112 million proposed deal that the FTC approved on June 7.
Within 10 days of the deal closing, Hikma must...
Subscription required to view this article.
This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login
to access this content
If you do not currently subscribe to FTCWatch please contact us for subscription information:
FTCWatch is delivered in the following formats: via email alert and online at mlexwatch.com/ftcwatch